Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Transauricular Vagus Nerve Stimulation Frequencies for Postoperative Pain (TVNS-PAIN)

7 juin 2026 mis à jour par: Joao Paulo Aureliano de Carvalho, Federal University of Bahia

Effects of Different Frequencies of Transauricular Vagus Nerve Stimulation on Postoperative Pain: A Randomized, Double-Blind, Sham-Controlled Trial With Preoperative and Postoperative Sessions

The goal of this clinical trial is to learn whether different frequencies of transauricular vagus nerve stimulation (tVNS) can reduce postoperative pain and opioid consumption in adults undergoing abdominal or urologic surgery. It will also evaluate the effects of tVNS on recovery quality, autonomic function, and treatment safety. The main questions it aims to answer are:

Does transauricular vagus nerve stimulation reduce postoperative opioid consumption during the first 24 hours after surgery? Do different stimulation frequencies (high-frequency and low-frequency tVNS) produce different effects on postoperative pain and autonomic responses? Is transauricular vagus nerve stimulation safe and well tolerated in surgical patients?

Researchers will compare high-frequency tVNS, low-frequency tVNS, and sham stimulation (inactive stimulation) to determine their effects on postoperative pain and opioid requirements.

Participants will:

Be randomly assigned to receive high-frequency tVNS, low-frequency tVNS, or sham stimulation.

Receive two 30-minute stimulation sessions, one before anesthesia and one after surgery in the post-anesthesia care unit.

Undergo assessments of postoperative pain, opioid consumption, need for rescue analgesics, postoperative nausea and vomiting, heart rate changes, and quality of recovery.

Be monitored for adverse events related to the intervention during the study period.

A total of 174 participants will be enrolled in this single-center, randomized, double-blind, sham-controlled clinical trial.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Postoperative pain remains a major challenge in perioperative care and is associated with delayed recovery, increased healthcare utilization, and greater opioid consumption. Despite advances in multimodal analgesia, opioid medications continue to play a central role in postoperative pain management and may be associated with adverse effects such as nausea, vomiting, respiratory depression, and prolonged recovery. Therefore, the development of effective non-pharmacological adjunctive strategies is of considerable clinical interest.

Transauricular vagus nerve stimulation (tVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve through the external ear. Experimental and clinical studies suggest that vagal stimulation may modulate pain perception through activation of central autonomic pathways, enhancement of descending inhibitory pain mechanisms, and regulation of inflammatory responses. Previous clinical trials have demonstrated promising effects of tVNS on acute and chronic pain conditions, including reductions in postoperative pain scores.

However, the optimal stimulation parameters for perioperative analgesia remain uncertain. In particular, the influence of stimulation frequency on clinical outcomes and autonomic responses has not been adequately investigated. Different stimulation frequencies may activate distinct neural pathways and produce different effects on pain modulation and autonomic regulation.

This study is designed to evaluate the effects of different frequencies of transauricular vagus nerve stimulation applied before and after surgery in adult patients undergoing elective surgical procedures. In addition to assessing postoperative opioid requirements, the study will explore the relationship between autonomic responses and postoperative recovery. The findings may contribute to the optimization of non-pharmacological analgesic strategies and support the incorporation of transauricular vagus nerve stimulation into multimodal perioperative pain management protocols.

Type d'étude

Interventionnel

Inscription (Estimé)

174

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Rodrigo L Alves, MD, PhD
  • Numéro de téléphone: 71 99961-9818
  • E-mail: rlalves@ufba.br

Sauvegarde des contacts de l'étude

Lieux d'étude

  • Brésil
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brésil, 40170-110
        • Recrutement
        • Hospital Universitário Professor Edgard Santos, Federal University of Bahia (HUPES-UFBA)
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Adults aged 18 to 59 years.
  • Undergoing elective abdominal or urologic surgery.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • History of neurological disorders.
  • History of psychiatric disorders.
  • Inability to understand study procedures.
  • Pregnancy.
  • Cognitive impairment.
  • Communication difficulties that interfere with study assessments.
  • Auricular dermatitis or skin lesions at the stimulation site.
  • Pre-existing cardiac arrhythmia.
  • Chronic opioid use.
  • Implanted electronic medical devices, including pacemakers.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: High-Frequency tVNS
Participants will receive active transauricular vagus nerve stimulation (tVNS) at a frequency of 60-120 Hz. Stimulation will be applied bilaterally to the auricular branch of the vagus nerve for 30 minutes before anesthesia and for 30 minutes after surgery. Current intensity will be adjusted between 2 and 6 mA according to participant tolerance.
Dispositif: Transauricular Vagus Nerve Stimulation (tVNS)
Non-invasive electrical stimulation of the auricular branch of the vagus nerve applied bilaterally through ear electrodes. Stimulation is delivered before anesthesia and after surgery using predefined frequency settings.
Expérimental: Low-Frequency tVNS
Participants will receive active transauricular vagus nerve stimulation (tVNS) at a frequency of 10-20 Hz. Stimulation will be applied bilaterally to the auricular branch of the vagus nerve for 30 minutes before anesthesia and for 30 minutes after surgery. Current intensity will be adjusted between 2 and 6 mA according to participant tolerance.
Dispositif: Transauricular Vagus Nerve Stimulation (tVNS)
Non-invasive electrical stimulation of the auricular branch of the vagus nerve applied bilaterally through ear electrodes. Stimulation is delivered before anesthesia and after surgery using predefined frequency settings.
Comparateur factice: Sham tVNS
Participants will receive sham transauricular vagus nerve stimulation. The device will be positioned and activated to mimic active treatment, but stimulation will be discontinued shortly after initiation. Participants will undergo two 30-minute sessions, one before anesthesia and one after surgery, while maintaining blinding to treatment allocation.
Dispositif: Sham Transauricular Vagus Nerve Stimulation (sham tVNS)
Sham stimulation delivered using the same device and electrode placement as active stimulation. The device is activated to mimic treatment but does not deliver therapeutic electrical stimulation.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Total postoperative opioid consumption during the first 24 hours after surgery
Délai: 24 hours after surgery
Total opioid consumption during the first 24 postoperative hours, recorded according to the institutional postoperative analgesia protocol.
24 hours after surgery

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Postoperative pain intensity (VAS)
Délai: Before stimulation in the post-anesthesia care unit, immediately after stimulation, 2 hours after surgery, and 24 hours after surgery
Pain intensity measured using a 100-mm Visual Analog Scale (VAS). Pain scores will be assessed at predefined postoperative time points and compared among study groups.
Before stimulation in the post-anesthesia care unit, immediately after stimulation, 2 hours after surgery, and 24 hours after surgery
Rescue analgesic use
Délai: Within 24 hours after surgery
Number of participants requiring rescue analgesics and total rescue analgesic administration during the first 24 postoperative hours.
Within 24 hours after surgery
Postoperative nausea and vomiting (PONV)
Délai: Within 24 hours after surgery
Incidence of postoperative nausea and/or vomiting and use of rescue antiemetic medication during the postoperative period.
Within 24 hours after surgery
Heart rate changes
Délai: Immediately before and immediately after each stimulation session (preoperative and postoperative).
Changes in heart rate measured immediately before and immediately after transauricular vagus nerve stimulation sessions as an indicator of autonomic nervous system activity.
Immediately before and immediately after each stimulation session (preoperative and postoperative).
Quality of Recovery (QoR-15 Score)
Délai: Baseline (preoperative) and 24 hours after surgery.
Quality of postoperative recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15). Higher scores indicate better recovery.
Baseline (preoperative) and 24 hours after surgery.
Adverse events related to transauricular Vagus Nerve Stimulation
Délai: From the first stimulation session until 24 hours after surgery.
Incidence of adverse events potentially related to the intervention, including auricular discomfort, skin irritation, headache, bradycardia, hypotension, bronchospasm, or other treatment-related events.
From the first stimulation session until 24 hours after surgery.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Federal University of Bahia

Collaborateurs

Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil

Les enquêteurs

  • Chercheur principal: Rodrigo M Vieira, MD, Botucatu Medical School, São Paulo State University (UNESP)

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juin 2026

Achèvement primaire (Estimé)

30 novembre 2026

Achèvement de l'étude (Estimé)

4 décembre 2026

Dates d'inscription aux études

Première soumission

2 juin 2026

Première soumission répondant aux critères de contrôle qualité

2 juin 2026

Première publication (Réel)

8 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

10 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 juin 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 96691226.0.0000.0049 (Identificateur de registre: 8.416.413)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data underlying the results reported in publications arising from this study will be made available, including demographic characteristics, intervention allocation, primary and secondary outcome measures, and adverse event data. Data will be shared only after removal of all direct identifiers to protect participant confidentiality.

Délai de partage IPD

De-identified individual participant data and supporting study documents will be available beginning 3 months after publication of the primary study results and will remain available indefinitely, with no end date.

Critères d'accès au partage IPD

De-identified data will be available to qualified researchers who provide a methodologically sound research proposal. Requests should be submitted to the principal investigator. Access will be granted following review and approval of the proposed use and execution of a data-sharing agreement.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner